Sagimet Biosciences Inc. filed a Form 8-K on August 13, 2026, reporting that the U.S. Food and Drug Administration cleared the company's Investigational New Drug application and issued a "Study May Proceed" letter for a Phase 3 clinical trial of denifanstat in moderate to severe acne.

Key Highlights

  • FDA IND clearance: The U.S. Food and Drug Administration cleared Sagimet's Investigational New Drug application for denifanstat.
  • "Study May Proceed" letter issued: The FDA issued a "Study May Proceed" letter in connection with the cleared IND.
  • Phase 3 trial: The cleared IND covers a Phase 3 clinical trial of denifanstat.
  • Target indication: The trial targets moderate to severe acne.
  • Drug class: Denifanstat is described in the filing as a fatty acid synthase inhibitor.
  • Report date: The event and filing both occurred on August 13, 2026.

FDA Clears Sagimet's IND Application for Denifanstat in Moderate to Severe Acne

According to the Form 8-K filed with the Securities and Exchange Commission on August 13, 2026, Sagimet Biosciences Inc. (NASDAQ:SGMT) announced that the U.S. Food and Drug Administration cleared the company's Investigational New Drug application for denifanstat. The FDA also issued a "Study May Proceed" letter, as disclosed by the company under Item 8.01 (Other Events).

The filing describes denifanstat as a fatty acid synthase inhibitor. The IND clearance and accompanying FDA letter pertain specifically to a Phase 3 clinical trial targeting moderate to severe acne. The company disclosed no additional clinical, financial, or operational details in the filing beyond those related to this regulatory action.

Sagimet Biosciences is incorporated in Delaware, headquartered at 950 Tower Lane, Suite 1500, Foster City, CA 94404, and qualifies as an emerging growth company as defined under applicable securities regulations. The 8-K was signed by David Happel, Chief Executive Officer, on August 13, 2026.

What Was Disclosed

Sagimet Biosciences disclosed that the FDA cleared its IND application and issued a "Study May Proceed" letter for a Phase 3 trial of the fatty acid synthase inhibitor denifanstat in moderate to severe acne, with both the event and filing dated August 13, 2026.